经典名方理冲汤的处方考证及治疗卵巢癌的 网络药理学研究

Prescription Textual Research and Network Pharmacology Study of Lichong Decoction in the Treatment of Ovarian Cancer

摘要: 目的：系统考证经典名方理冲汤的处方源流与历史沿革，并运用网络药理学和分子对接方法预测其治疗卵巢癌的潜在作用机制。方法：通过检索《中华医典》及CNKI、万方等数据库，对理冲汤的来源、方义衍变、组方配伍、剂量煎法、药物基原及炮制进行考证。利用TCMSP、TCMID数据库筛选理冲汤活性成分及靶点，通过GeneCards、CTD、TTD数据库获取卵巢癌疾病靶点，取交集后构建蛋白相互作用网络，进行GO和KEGG富集分析，并运用AutoDock进行分子对接验证。结果：理冲汤出自张锡纯《医学衷中参西录》，由生黄芪、党参、生白术、生山药、天花粉、知母、三棱、莪术、生鸡内金9味药组成，体现“扶正祛邪，攻补兼施”之旨。网络药理学筛选得到活性成分103个，对应靶点605个，卵巢癌相关靶点1153个，交集靶点151个。核心活性成分为槲皮素、山柰酚、木犀草素等，核心靶点涉及AKT1、TP53、STAT3、JUN、TNF等。GO功能富集获得生物学过程条目1856个，KEGG富集获得信号通路189条，主要涉及PI3K-Akt、MAPK、IL-17、TNF等通路。分子对接显示核心成分与核心靶点结合稳定。结论：理冲汤组方严谨，古今沿用一致。其治疗卵巢癌具有多成分、多靶点、多通路特点，可能通过槲皮素、山柰酚等调控AKT1、TP53等靶点，干预PI3K-Akt、MAPK等通路，抑制肿瘤细胞增殖、诱导凋亡、抗炎及调节免疫微环境。

Abstract: Objective: To systematically verify the origin and evolution of Lichong Decoction, and to predict its potential mechanism in the treatment of ovarian cancer using network pharmacology and molecular docking. Methods: The source, evolution of the formula’s meaning, composition and compatibility, dosage and decoction method, drug origin and preparation of Lichong Decoction were researched through Chinese Medical Classics, CNKI and Wanfang databases. Active components and targets of Lichong Decoction were screened from TCMSP and TCMID. Ovarian cancer-related targets were obtained from GeneCards, CTD, and TTD. The intersection targets were used to construct PPI networks, followed by GO, KEGG enrichment and molecular docking verification using AutoDock. Results: Lichong Decoction was first recorded in Yixue Zhongzhong Canxilu by Zhang Xichun, consisting of 9 herbs: raw Astragalus mongholicus (Huangqi), Codonopsis pilosula (Dangshen), raw Atractylodes macrocephala (Baizhu), raw Dioscorea opposita (Shanyao), Trichosanthes kirilowii (Tianhuafen), Anemarrhena asphodeloides (Zhimu), Sparganium stoloniferum (Sanleng), Curcuma phaeocaulis (Ezhu), and raw Gallus gallus domesticus (Jineijin). This formulation embodies the therapeutic principle of “strengthening vital Qi to eliminate pathogenic factors, and simultaneous application of tonifying and purging methods”. A total of 103 active components, 605 drug targets and 1153 disease targets were obtained, with 151 common targets. The key components were quercetin, kaempferol and luteolin; core targets included AKT1, TP53, STAT3, JUN and TNF. GO enrichment showed 1856 biological processes; KEGG enrichment showed 189 signaling pathways, mainly including PI3K-Akt, MAPK, IL-17 and TNF pathways. Molecular docking confirmed stable binding of core components and core targets. Conclusion: Lichong Decoction has a rigorous composition and has been consistently used throughout history. Its treatment of ovarian cancer has the characteristics of multiple components, multiple targets, and multiple pathways. It may regulate AKT1, TP53, etc. through quercetin, kaempferol, etc., and intervene in pathways such as PI3K-Akt, MAPK, etc., inhibiting tumor cell proliferation, inducing apoptosis, anti-inflammatory, and regulating the immune microenvironment.